Please provide your email address to receive an email when new articles are posted on . Meaningful progress is being made in the development of gene therapies for rare neurological diseases caused by ...
As gene therapy evolves to target additional indications—including more common indications—the choice of delivery platform is bound to become more interesting. At present, the most common delivery ...
AAVs are attractive viral vectors for gene therapy due to their lack of pathogenicity, low immunogenicity, broad tropism and persistent transgene expression in both proliferating and quiescent cells.
What Are AAV Vector-Based Therapies? Gene therapies are groundbreaking approaches utilizing viral and non-viral vectors. These vectors introduce therapeutic genes into patient cells to treat diseases, ...
Adeno-associated viral vectors comprise the majority of recent gene therapy development programs due to their broad tissue-tropism and relatively low immunogenicity. Recent gene therapy approvals, ...
AI-assisted adeno-associated virus (AAV) capsid engineering has transformative potential in terms of accelerating and optimizing the development of gene therapies. That’s the view of Fangzhi Tan, PhD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results